A Study of Elenestinib in Healthy Adult Female Participants
Phase 1
18–65
Female only
1 site in AZ
About this study
This Phase 1 study is testing Elenestinib in people with healthy volunteers. The primary outcome being measured is Apparent first-order terminal elimination half-life (t1/2).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
kinase inhibitor, ethinylestradiol, progestin (hormonal contraceptive), midazolam (Benzodiazepine; short-acting)
oral (Oral Tablet), injection
Primary: Apparent first-order terminal elimination half-life (t1/2), Apparent total plasma clearance after oral administration (CL/F), Maximum observed concentration (Cmax), Percent of AUC0-inf extrapolated (AUC%extrap), Time to reach Cmax (Tmax)
Secondary: Number of participants with treatment-emergent adverse events (TEAEs)